ORKA-001
Moderate-to-Severe Plaque Psoriasis
Key Facts
About Oruka Therapeutics
Oruka Therapeutics' mission is to develop and commercialize novel biologic therapies for autoimmune and inflammatory diseases, with an initial clinical focus in dermatology. Its primary achievement is advancing its lead candidate into clinical trials for moderate-to-severe plaque psoriasis, a key milestone validating its research approach. The company's strategy is to generate compelling clinical proof-of-concept data in this initial indication to de-risk its platform and create value, while laying the groundwork for potential expansion into adjacent autoimmune conditions. As a public entity, Oruka is executing a capital-efficient, focused development plan to reach key inflection points.
View full company profileAbout Oruka Therapeutics
Oruka Therapeutics' mission is to develop and commercialize novel biologic therapies for autoimmune and inflammatory diseases, with an initial clinical focus in dermatology. Its primary achievement is advancing its lead candidate into clinical trials for moderate-to-severe plaque psoriasis, a key milestone validating its research approach. The company's strategy is to generate compelling clinical proof-of-concept data in this initial indication to de-risk its platform and create value, while laying the groundwork for potential expansion into adjacent autoimmune conditions. As a public entity, Oruka is executing a capital-efficient, focused development plan to reach key inflection points.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| ICOTYDE (icotrokinra) | Johnson and Johnson Innovative Medicine | Approved |
| ILUMYA® (tildrakizumab-asmn) | Sun Pharmaceutical | Commercial |
| Iruxolimab (AK101) | Akeso | Approved |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Approved |
| Envudeucitinib (ESK-001) | Alumis | Phase 3 |